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Background. The prognostic importance of α-fetoprotein (AFP) level elevation in patients with chronic hepatitis C and its clinical
signiﬁcance in steatosis associated with HCV infection remain to be determined. The present paper assessed clinical signiﬁcance
of elevated AFP in patients with CHC with and without steatosis. Methods. One hundred patients with CHC were divided into 50
patients with CHC and steatosis and 50 patients with CHC and no steatosis based on liver biopsy. Results. AFP was signiﬁcantly
increased in CHC with steatosis than patients without steatosis (P<0.001). Highly signiﬁcant positive correlation was found
between serum AFP and necroinﬂammation as well as the severity of ﬁbrosis/cirrhosis and negative signiﬁcant correlation with
albuminlevelinchronicHCVwithsteatosis(P<0.001)butnegativenonsigniﬁcantcorrelationwithALTandASTlevel(P ≤ 0.778
and 0.398), respectively. Highly signiﬁcant increase was found in chronic hepatitis patients with steatosis than CHC without
steatosis regarding necroinﬂammation as well as the severity of ﬁbrosis/cirrhosis and AFP (P<0.001). Conclusion. Patients with
chronic HCV and steatosis have a higher AFP levels than those without steatosis. In chronic HCV with steatosis, elevated AFP
levels correlated positively with HAI and negative signiﬁcant correlation with albumin level.
1.Introduction
Chronic hepatitis C (CHC) is thought to aﬀect more than
170 million people worldwide, and it has been shown that
steatosis occurs in approximately 50% of patients with CHC
[1]. Steatosis also occurs more than twice as frequently
in patients with CHC than in the general population [2].
Both viral and host metabolic factors have been reported
to contribute to the genesis of hepatic steatosis in patients
with CHC. Most steatosis is mild, with the more severe cases
usually occurring in genotype 3 virus infection [3].
Serum alpha-fetoprotein (AFP) is a fetal glycoprotein
produced by the yolk sac and fetal liver [4]. Following
birth, AFP levels decrease rapidly to less than 20ng/mL
and increase signiﬁcantly in certain pathologic conditions.
Serum AFP is a debated but routinely used marker for
hepatocellular carcinoma (HCC) in patients with chronic
liver disease [5]. Benign circumstances that may produce
elevations of AFP include cirrhosis, hepatic necrosis, acute
hepatitis, chronic active hepatitis, ataxia-telangiectasia, and
pregnancy [6, 7]. Elevated serum AFP levels may also be
due to altered hepatocyte-hepatocyte interaction and the
loss of normal architectural arrangements [8]. Based on the
results of Ray et al. about 91% of the Egyptian patients with
chronic HCV were infected with HCV genotype 4 [9]. In this
study, we evaluated serum AFP and its clinical signiﬁcance in
EgyptianpatientswithchronichepatitisCmostlygenotype4
(based on the results of Ray et al.) with and without steatosis.
2.SubjectsandMethods
This prospective study included 100 patients with CHC
divided into two groups (50 patients with steatosis and
50 patients without steatosis) based on liver biopsy. Both
groups were adjusting as regarding age, sex, and for risk
factors for steatosis (BMI, DM, and hyperlipidemia). They2 International Journal of Hepatology
werereferredtoMansourauniversityHospital,fromOctober
2010 to December 2011, for liver biopsy and searching for
chronic HCV management. The study protocol conﬁrmed
to the ethical guidelines of 1975 Declaration of Helsinki.
Informed consent was obtained from all patients. CHC was
deﬁnedaccordingtopositiveserumHCV-AbandHCV-RNA
for at least 6 months and elevated levels of serum amino-
transferases (AST, ALT). The patient’s medical histories
were taken including, age, gender, weight, height, and body
mass index (BMI). AFP was studied with ELISA method
using Abbott laboratory reagents, USA (normal level of
AFP was deﬁned as <8.1ng/mL); serum fasting triglyceride,
fasting blood sugar, albumin, AST, ALT, total bilirubin,
and HCV-RNA viral load were determined. Biochemical
tests and HCV-RNA (viral load IU/mL) were performed
by autoanalyzer (Selecta, Germany) and Cobas Amplicore
monitor version 2 (Roche Molecular Systems, Branchburgh,
NJ, USA), respectively. BMI was calculated by the following
formula: weight (kg)/height2 (m2).
Exclusion criteria were patients with diabetes mellitus,
hypertension, and patients who had any serological evidence
of infection with other viruses (HBV and HIV); all other
known causes of liver diseases were excluded on the basis of
analytical, clinical, and epidemiological data: autoimmunity,
metabolic and genetic disorders, NASH, alcohol intake,
drug toxicity, and patients with decompensated cirrhosis.
Hepatocellular carcinoma and other causes of high levels of
AFP like cancer of the testes or ovaries and metastatic liver
cancer were excluded using ultrasound as the predominant
screening method.
Percutaneous liver biopsy (≥15mm in length) was
performed for all the patients. Liver biopsy specimens were
reviewed by a single pathologist. For each liver biopsy spec-
imen, hematoxylin and eosin and Masson’s trichrome stains
were available. The extent of hepatic steatosis was assessed
and graded as none (steatosis < 5%), mild steatosis (steatosis
5–33%ofhepatocytes),moderatesteatosis(steatosis34–66%
of hepatocytes), and sever (steatosis > 66% of hepatocytes)
according to histological scoring system of Kleiner et al.
[10]. The histological activity (grade) and degree of ﬁbrosis
(stage) of the liver biopsy were assessed according to the
modiﬁed histological activity index (HAI) of Ishak et al.
[11]. Histological activity was considered as minimal (score
1–3), mild (4–8), moderate (9–12), and severe (13–18).
Fibrosis was staged separately on a scale 0–6, corresponding
to no ﬁbrosis (0), mild (1-2), moderate (3-4), and severe or
cirrhosis (5-6).
3.StatisticalAnalysis
The statistical analysis of data was done by using Excel
program and SPSS program (statistical package for social
science) version 10. Data are expressed as the mean ±
SD. Mean values were compared with the Student’s t-test
(variables with normal distribution) or Mann-Whitney U-
test (variables with nonnormal distribution). Categorical
variables were compared using the chi-square test. Cor-
relations were done using Pearson’s correlation. All the
tests performed were two sided and a P value < 0.05 was
considered to be statistically signiﬁcant.
4. Results
This prospective study included 100 patients with CHC (50
patients with steatosis and 50 patients without steatosis) as
evidenced by liver biopsy. All patients were positive for anti-
HCV antibodies and positive HCV RNA. Table 1 shows the
comparison of clinical, biochemical, and histopathological
characteristicsofpatientswithandwithoutsteatosis.Patients
with steatosis had a signiﬁcantly higher AFP (P<0.001) and
necroinﬂammation and ﬁbrosis/cirrhosis (P<0.001). Also
AST (P<0.001), ALT (P = 0.002), total Bilirubin (P =
0.023), and prothrombin time (P = 0.003) were signiﬁcant
high in chronic HCV with steatosis than without steatosis.
However, age, triglyceride, fasting blood glucose, albumin,
BMI, and HCV RNA were not signiﬁcantly diﬀerent between
the two groups.
Table 2 showed a signiﬁcant positive correlation between
higher serum AFP levels, with the severity of periportal
necroinﬂammation, as well as the severity of ﬁbrosis/cirrho-
sis (P<0.001). A signiﬁcant negative correlation was found
between serum AFP and serum albumin (P<0.001). Also
a negative correlation but not signiﬁcant was found between
serum AFP, AST (P = 0.398), and ALT (P = 0.778).
5. Discussion
Hepatitis C virus (HCV) is a member of the Flaviviridae
family responsible for acute and chronic liver disease [12].
Infection with HCV is common, with an average worldwide
prevalence of 3% [13]. Acute HCV infection becomes
persistent in about 85% of cases [14] and may cause chronic
hepatitis leading to cirrhosis and, eventually, hepatocellular
carcinoma [15].
The reported prevalence of steatosis in patients with
chronic hepatitis C varies between 40% and 80%, depending
on the features of the population studied in terms of
alcohol consumption, prevalence of obesity, diabetes, and
other risk factors [16]. The prevalence of steatosis in HCV
is approximately 2-fold higher than in another common
chronic liver disease like hepatitis B [17], suggesting that
HCV may directly cause steatosis, at least in some patients.
All genotypes are steatogenic, but numerous reports showed
that steatosis was more frequent and more severe in patients
infected with genotype 3 [18–20].
AFP is a glycoprotein that is normally generated during
conception by the fetal liver and yolk sac. In clinical practice,
AFP levels are elevated in various clinical situations, which
include hepatocellular carcinoma, acute or chronic viral
hepatitis, chronic liver disease, and gonadal tumors [21].
In this study we tried to determine the level of AFP
among patients with chronic HCV, and evaluate its relation
to the presence of steatosis among 100 patients with chronic
HCV (50 with steatosis and 50 without steatosis) enrolled in
our study.International Journal of Hepatology 3
Table 1: Clinical, biochemical and histopathological characteristics of patients with and without steatosis.
Steatosis + VE Steatosis − VE P value
Age (years) 41.62 ±6.37 43.68 ±6.94 0.126
Grade (Ishak grading) 5.90 ±2.21 2.48 ±.1.50 0.001∗
Stage of ﬁbrosis (Ishak staging) 2.72 ±1.93 .50 ±.50 0.001∗
AFP (ng/mL) 8.64 ±3.18 3.56 ±.81 0.001∗
Triglyceride (mg/dL) 108.95 ±26.39 102.68 ±31.65 0.323
FB glucose (mg/dL) 106.76 ±75.84 101.31 ±14.35 0.44
Alumin (g/dL) 4.40 ±.30 4.50 ±.28 0.115
AST (u/L) 53.62 ±20.83 34.42 ±15.26 0.001∗
ALT (u/L) 57.72 ±20.43 45.22 ±18.47 0.002∗
Total Bilirubin (mg/dL) 0.82 ±.35 0.62 ±.34 0.023∗
Prothrombin time concentration % 88.09 ±7.39 84.50 ±3.64 0.003∗
BMI 29.3 ±5.22 8 .9 ±3.2 0.695
HCV RT-RNA (IU/mL) 224529.1 ±308275.96 298415.9 ±320004.30 0.302
AFP, Alpha-fetoprotein; FB glucose, Fasting blood glucose; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BMI, body mass index;R T - P C R ,
reverse transcriptase-polymerase chain reaction.
Table 2: The Pearson’s Correlation between pathological and
biochemical parameters with AFP in CHC patients with steatosis.
AFP
RP
Necroinﬂammation ∗0.759 0.001
Fibrosis ∗0.759 0.001
Albumin (g/dL) −0.710 0.001
ALT (u/L) −0.041 0.778
AST (u/L) −0.122 0.398
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
S i m i l a rt op r e v i o u ss t u d i e s[ 6, 7] we found that AFP was
increased in patients with chronic HCV in the current study.
Although both groups (with or without steatosis) are similar
regarding underlying etiology (HCV) and were adjusting for
r i s kf a c t o r so fh i g hl e v e l so fA F Pa n ds t e a t o s i s ,A F Pw a s
highly signiﬁcant among patients with chronic HCV and
steatosis than patients without steatosis. Regarding necroin-
ﬂammmation and ﬁbrosis/cirrhosis, a signiﬁcant increase in
patients with HCV and steatosis than without steatosis was
found. Our results were consistent with the previous reports
[22, 23] which revealed that HCV is associated with steatosis
in a large portion of cases and that steatosis is associated with
worsening ﬁbrosis. In addition, steatosis induces chronic
hepatic inﬂammation, reactive oxygen species, and DNA
damage in animal models [24–26]. So steatosis is associated
with more degree of inﬂammation and ﬁbrosis. Hepatic
progenitor cells (HPCs) arise in the periportal region of the
liver and may be responsible for liver regeneration. They
express high levels of AFP, certain keratin markers, and GGT
[27–29]. Their presence is related to the severity of ﬁbrosis
[30], and their activation has been documented in parallel
withcellsassociatedwiththedevelopmentofﬁbrosis(stellate
cells) [31]. Since steatosis among patients with chronic HCV
infection was associated with an increase in both the number
of HPC and the extent of the ductular reaction as provided
by Clouston et al., so these provide a potential mechanism
whereby steatosis contributes to the increase in AFP [32].
Another explanation of increased AFP was provided
by the results of others [27–31]; they concluded that the
presence of more ﬁbrosis is associated with increasing
number and more activation of hepatic progenitor cells.
Since the group with steatosis has more ﬁbrosis/cirrhosis
than group without steatosis, hence, the joint association
observed in this study among increased AFP in chronic HCV
with steatosis than none steatotic group.
The aminotransferases are also important biological
markers that are widely used for liver diseases. Elevation
of the activity of these enzymes in serum is believed to
result from their leakage from damaged cells, and so this
reﬂects hepatocyte injury. These enzymes are elevated in
many forms of liver diseases and especially those diseases
that are associated with signiﬁcant hepatocyte necrosis such
as acute viral hepatitis, which is the most common cause of
massive aminotransferases elevation [33]. In this study the
levels of aminotransferases AST and ALT are signiﬁcantly
increased in chronic HCV with steatosis than patients
without steatosis, indicating more hepatocytes necrosis in
patients with steatosis. Our result was in agreement with
Hepburn et al., who found signiﬁcant increase in ALT and
AFP level among patients with steatosis versus without
steatosis [34].
OurresultsshowedthatserumAFPlevelswerecorrelated
with the severity of periportal necroinﬂammation as well as
the severity of ﬁbrosis/cirrhosis among chronic HCV with
steatosis. These results were consistent with the report of
Chu et al., which revealed that higher serum AFP levels were
correlated with the severity of periportal necroinﬂammation
as well as the severity of ﬁbrosis/cirrhosis. AFP production
is enhanced in the presence of injury, possibly resulting4 International Journal of Hepatology
from increased hepatocyte turnover [35]. Hu et al. found
a similar correlation between AFP and measures of liver
disease activity and severity [36]. The obvious increase in
AFP and biochemical values suggests that inﬂammation,
necrosis, and hepatocellular injury are the most common
cause of elevated AFP in the studied groups.
In our study a negative correlation was found between
lowerserumalbuminandAFPamongpatientswithsteatosis.
According to previous reports, the AFP and albumin genes
are characteristically arranged in tandem by a similar
structure and are believed to be derived from a common
a n c e s t r a lg e n e[ 37]. Previous reports have described that
reciprocal changes in albumin and AFP gene transcription
existed during liver regeneration [38, 39]. The possible
mechanism may attribute to the switching action of the
AFP enhancer from the AFP promoter to the albumin
promoter,whichleadstoadecreaseinAFPexpressionandan
increase in albumin expression [37]. Thus, in patients with
chronic Hepatitis C, a reactive expression of the AFP gene,
as shown in hepatic necroinﬂammation and hepatocellular
proliferation, may be associated with a decrease in albumin
gene transcription and may lead to a lower serum albumin
level.
The relationship between the level of aminotransferases
and AFP is not deﬁnite as a rise in the level of aminotrans-
ferasesenzymescanbeanattributetodamageofhepatocytes,
while the level of AFP, and especially a markedly increased
level (>400ng/mL), is rather due to a neoplasm, hepato-
cellular carcinoma [33]. In this study a negative correlation
between the ALT, AST, and AFP (Table 2)w a sf o u n db u t
not statistically signiﬁcant. Chu et al. found no signiﬁcant
diﬀerent in serum transaminase levels in patients with or
without elevated serum AFP [35], but against this result is
that of Goldstein et al., who found that increasing serum
AFP values were signiﬁcantly correlated with increasing ALT
values [8].
There seems to be important correlations among the
necroinﬂammationaswellastheseverityofﬁbrosis/cirrhosis
and albumin with serum AFP. The necroinﬂammation as
well as the severity of ﬁbrosis/cirrhosis and a lower serum
albumin was shown to be predictor for elevation of serum
AFP among chronic HCV with steatosis.
Our results were consistent with the report from Bayati
et al., which revealed that an elevated serum AFP level was
highly speciﬁc for the diagnosis of cirrhosis among patients
with chronic hepatitis C. These ﬁndings indicated that
hepatic ﬁbrosis/cirrhosis is more important than necroin-
ﬂammation in causing an elevation of serum AFP in patients
with chronic hepatitis C [40]. Also chu et al. found that
a lower serum albumin level was an independent factor in
predicting elevated serum AFP [35].
In conclusion, this study has demonstrated that patients
with chronic HCV and steatosis have higher AFP levels than
those without steatosis. AFP correlates with necroinﬂamma-
tion as well as the severity of ﬁbrosis/cirrhosis in chronic
HCV with steatosis. Higher levels of serum AFP may corre-
spond to the presence of steatosis among chronic HCV. They
increased both the number of HPC and the extent of the
ductular reaction in addition to increased ﬁbrosis/cirrhosis
levels providing a potential mechanism whereby steatosis
contributes to the increase in AFP. So in the absence of
traditional causes of elevated serum AFP, steatosis should
be among the diﬀerential diagnoses of elevated serum AFP
levels in patients with chronic HCV infection.
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